NTLA (NASDAQ) - Intellia Therapeutics Inc

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45826J1051
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Web URL: https://www.intelliatx.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for NTLA (NASDAQ) - Intellia Therapeutics Inc


Market Cap in USD 2,850m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2016-05-06


Fundamental -5.63
Dividend -
Performance 5y 1.09
Rel. Performance vs Sector -1.27
Analysts 4.46
Fair Price Total Ret. 28.02
Fair Price DCF todo


Growth TTM -46.08%
CAGR 5y 3.12%
CAGR / Mean Drawdown 5y 0.07
Sharpe Ratio TTM -0.88
Alpha vs SP500 TTM -79.24
Beta vs SP500 5y weekly 1.68
CAPM 8.94%
Average Daily Range 2m 3.25%
Reversal Oscillator 14.72
Volatility GJR Garch 1y 43.90%
Price / SMA 50 -16.15%
Price / SMA 200 -19.56%
Current Volume 754.8k
Average Volume 20d 819.8k


Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%